Dyslipidemia and atherosclerosis in type 2 diabetes mellitus patients. Statin therapy characteristics and comparative analysis: endocrinologist’s point of view

Cover Page

Cite item

Full Text

Abstract

Patients with type 2 diabetes mellitus (DM type 2) are in a high-risk group of cardiovascular disease (CVD) development, and coexisting DM type 2 and CVD contribute to high mortality risk. Statin use in DM type 2 patients for CVD prevention is one of the key concepts of modern antidiabetic therapy. It is statins which are considered as first line hypolipidemic therapy in DM type 2 patients according to international guidelines and DM treatment algorithm of Russian Diabetes Association. Target lipid profile values achievement is one of the major tasks in statin therapy. It was shown in multicenter randomized blind placebo-controlled clinical trials that patients who received rosuvastatin had the best results in cholesterol, triglycerides, LDL, and C-reactive protein level reduction. Rosuvastatin has a dose-dependent effect and can be recommended as treatment of choice

About the authors

T. Yu Demidova

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: t.y.demidova@gmail.com
д-р мед. наук, проф., зав. каф. эндокринологии лечебного фак-та 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

O. V Susareva

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

ординатор каф. эндокринологии лечебного фак-та 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

References

  1. Global report on diabetes. WHO, 2016. http://www.who.int/diabetes/global-report
  2. Федеральная служба государственной статистики. http://www.gks.ru
  3. Haffner S.M, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
  4. Nelson A.J, Rochelau S.K, Nicholls S.J. Managing Dyslipidemia in Type 2 Diabetes. Endo-crinol Metab Clin N Am 2018; 47: 153-73.
  5. Anderson T.J. Assessment and Treatment of Endothelial Dysfunction in Humans. J Am Coll Cardiol 1999; 34: 631-8.
  6. Katakami N. Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus. J Atheroscler Thromb 2018; 25: 27-39.
  7. Ross R. Atherosclerosis - An inflammatory Disease. N Engl J Med 1999; 340: 115-26.
  8. Libby P, Ridker P.M, Maseri A. Inflammation and atherosclerosis. Circ J 2002; 105: 1135.
  9. Libby P, Ridker P.M, Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-25.
  10. DeFronzo R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture. 2009. Diabetologia 2010; 53: 1270-87.
  11. Matsuzawa Y, Shimomura I, Nakamura T et al. Pathophysiology and Pathogenesis of Visceral Fat Obesity. Obes Res 1995; Suppl. 2: 187-94.
  12. Hsueh W.A, Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol 2003; 92: 3-9.
  13. Hajer G.R, van Haeften T.W, Visseren F.L.J. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959-71.
  14. Ritthaler U, Deng Y, Zhang Y et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 1995; 146: 688-94.
  15. Cipollone F, Fazia M, Iezzi A et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circ J 2003; 107: 1479-85.
  16. Tanji N, Markowitz G.S, Fu C et al. Expression of advanced glycation end products and their cellular receptorRAGEin diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1656-66.
  17. Brett J, Schmidt A.M, Yan S.D et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143: 1699-712.
  18. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 2017.
  19. Jung K.Y, Kyoung M.K, Han S.K et al. Effect of Rosuvastatin on Cholesterol Efflux Capacity and Endothelial Function in Type 2 Diabetes Mellitus and Dyslipidemia. Circ J 2017. doi: 10.1253/circj.CJ-17-0411
  20. Jellinger P.S, Handelsman Y, Rosenblit P.D et al. American Association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 2017; 23 (Suppl. 2): 1-87.
  21. Wolffenbuttel B.H.R, Franken A.A.M, Vincent H.H. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes - CORALL study. J Inter Med 2005; 257: 531-9.
  22. Gotto A.M, Whitney E, Stein E.A et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477-84.
  23. Walldius G, Jungner I, Holme I et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
  24. Nicholls S et al. Atheroscler Suppl 2009; 10: 965.
  25. Stalenhoef A.F et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005; 26: 2664-72.
  26. Nesto R. C-Reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 2004; 21: 810-7.
  27. Betteridge D.J, Gibson J.M, Sager P.T. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol 2007; 100: 1245-8.
  28. Ross R. Atherosclerosis - an inflammatory disease. N Eng J Med 1999; 340: 115-26.
  29. Jager A, van Hinsbergh V.W, Kostense P.J et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 3071-8.
  30. Jialal I, Miguelino E, Griffen S.C, Devaraj S. Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. J Clin Endocrinol Metab 2007; 92: 3136-40.
  31. Maedler K, Sergeev P, Ris F et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-60.
  32. Chamaria S, Johnson K.W, Vengrenyuk Y et al. Intracoronary Imaging, Cholesterol Effluxand Transcriptomics after Intensive Statin Treatment in Diabetes. Sci Rep 2017; 7 (1): 7001.
  33. Davies M.J, Richardson P.D, Woolf N et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-81.
  34. Moreno P.R, Falk E, Palacios I.F et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circ J 1994; 90: 775-8.
  35. Burke A.P, Kolodgie F.D, Zieske A et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004; 24: 1266-71.
  36. Dollery C.M, McEwan J.R, Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-8.
  37. Bellosta S, Via D, Canavesi M et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-8.
  38. Parathath S, Grauer L, Huang L.S et al. Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes 2011; 60: 1759-69.
  39. Кобалава Ж.Д., Виллевальде С.В. Терапия статинами и риск развития сахарного диабета. Эффективная фармакотерапия. Эндокринология. 2015; Спецвып. (11): 33-9.
  40. Проект клинических рекомендаций. Профилактика развития сахарного диабета типа 2: роль и место метформина. Эндокринология. Новости. Мнения. Обучение. 2017; 1: 1-9.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies